Full text is available at the source.
Lancet (London, England)···
Safety, body responses, and drug behavior of amycretin, a new combined GLP-1 and amylin receptor medicine, in a first human trial
Updated
Abstract
A total of 144 participants were enrolled in a phase 1 study evaluating the safety and tolerability of amycretin.
- 62% of participants experienced treatment-emergent adverse events, all categorized as mild or moderate.
- Gastrointestinal events accounted for 49% of the total adverse events reported.
- The frequency of adverse events increased in a dose-dependent manner.
- Amycretin plasma concentrations demonstrated dose proportionality across all treatment groups.
- No deaths were reported during the study.
Simplified
BACKGROUND: GLP-1 receptor agonists and amylin receptor agonists have shown clinically relevant weight loss and glucose-lowering effects in people with overweight, obesity, and type 2 diabetes. Amycretin is a novel, single-molecule GLP-1 receptor and amylin receptor agonist. We aimed to investigate the safety, tolerability, pharmacokinetic properties, and pharmacodynamic effects of single ascending doses (part A) and multiple ascending doses (parts B and C/D) of amycretin in adult participants with overweight or obesity.
METHODS: In this phase 1, first-in-human, randomised, double-blind, placebo-controlled multipart study, participants were recruited at a single clinical research unit in San Antonio (TX, USA). Eligible individuals were men or women (including women of childbearing potential) aged 18-55 years at the time of signing informed consent with a BMI of 25·0-34·9 kg/mfor parts A and B and a BMI of 27·0-39·9 kg/mfor part C/D. For part A, participants were randomly assigned across six treatment groups (single ascending doses of oral amycretin [1 mg, 3 mg, 6 mg, 12 mg, 18 mg (12 + 6 mg per adaptive study design), or 25 mg]) or placebo (6:2 to amycretin groups vs placebo). Part A consisted of a 28-day screening period, a 1-day (single dose) intervention period, and a 21-day follow-up period. In part B, participants were randomly assigned across three treatment groups (multiple ascending doses of oral amycretin [3 mg, 6 mg, or 12 mg once daily]) or placebo (9:3 to amycretin groups vs placebo). Part B consisted of a 28-day screening period, a 10-day intervention period, and a 21-day follow-up period. In part C/D, 60 participants were randomly assigned to one of three dose-escalation treatment groups (multiple ascending doses of oral amycretin in a fixed titration regimen for all participants [part C1: from 3 mg to 50 mg once daily; part C2: from 6 mg to 2 × 50 mg (two tablets in a single daily dose); and part D: from 3 mg to 2 × 25 mg (two tablets in a single daily dose)]), or placebo (16:4 to amycretin groups vs placebo). Part C/D consisted of a 4-week screening period, a 12-week intervention period, and a 3-week follow-up period. The primary endpoint was the number of treatment-emergent adverse events reported from before dosing on day 1 (baseline) until the end-of-study visit on day 22 (part A), day 31 (part B), or day 105 (part C/D). Supportive secondary pharmacokinetic endpoints for parts A-D were area under the amycretin plasma concentration-time curve and maximum plasma concentration. Exploratory pharmacodynamic endpoints in part C/D were change in bodyweight (%) and fasting plasma glucose (mmol/L) from before dosing on day 1 until day 85. The safety analysis set, comprising all participants who were exposed to treatment, was used to analyse the endpoints and assessments related to safety. The full analysis set, comprising all randomly assigned participants, was used to analyse endpoints related to pharmacokinetic and exploratory pharmacodynamic endpoints. This study is registered with ClinicalTrials.gov, NCT05369390. 2 2
FINDINGS: Between May 11, 2022, and Jan 9, 2024, 144 participants were enrolled in the study (48 participants in part A, 36 participants in part B, and 60 participants in part C/D). Across parts A-D, there were 364 treatment-emergent adverse events in 89 (62%) of 144 participants, all of which were mild or moderate in severity and increased in frequency in a dose-dependent manner. The most common treatment-emergent adverse events were gastrointestinal in nature (180 [49%] of 364 events), observed in 72 (81%) of 89 participants who reported a treatment-emergent adverse event. No deaths were reported. Amycretin plasma concentrations were consistent with dose proportionality across all treatment groups.
INTERPRETATION: In people with overweight or obesity, amycretin appeared safe and tolerable. Results from this first-in-human, phase 1 study support further investigation of the weight loss properties of amycretin.
FUNDING: Novo Nordisk A/S.
Related papers
Jun '25
Amycretin, a new drug activating appetite and blood sugar control receptors, tested by injection in an early clinical trial
top 1% journal
cited by 45 papers
randomized controlled trial
Jun '23
Retatrutide, a drug targeting three hormone receptors, for people with type 2 diabetes in a controlled US clinical trial
top 1% journal
cited by 344 papers
randomized controlled trial
Apr '21
Safety, body effects, and how the body processes multiple doses of cagrilintide combined with semaglutide 2.4 mg for weight loss
top 1% journal
cited by 282 papers
randomized controlled trial
Jun '18
MEDI0382, a drug targeting appetite and blood sugar control, tested in overweight and obese type 2 diabetes patients in a controlled dose study
top 1% journal
cited by 281 papers
randomized controlled trial
Nov '22
LY3437943, a new drug activating three hormone receptors, tested in people with type 2 diabetes in a controlled early-stage trial with increasing doses
top 1% journal
cited by 176 papers
randomized controlled trial
Dec '18
Early study testing different doses of MEDI4166, a combined cholesterol-lowering and blood sugar control drug, in overweight or obese people with type 2 diabetes
top 2% journal
cited by 14 papers
randomized controlled trial
Oct '18
Safety and effectiveness of LY3298176, a new drug targeting two hormone receptors, in people with type 2 diabetes: a controlled phase 2 trial
top 1% journal
cited by 714 papers
randomized controlled trial
Dec '15
Liraglutide's effectiveness and safety for overweight adults with type 1 diabetes and poor blood sugar control
top 1% journal
cited by 155 papers
randomized controlled trial
Nov '25
Orforglipron, an oral GLP-1 drug, for treating obesity in people with type 2 diabetes: a phase 3 placebo-controlled trial
top 1% journal
cited by 11 papers
randomized controlled trial
Jun '25
Effects and safety of the targeted drug ecnoglutide in adults with overweight or obesity: a large controlled clinical trial
top 1% journal
cited by 19 papers
randomized controlled trial